


# Anomalous Entity Report

## "Void Brain Disorder"



Subject - 0121<sup>1</sup>


<sup>1</sup>Department for Classification of Non-typical Phenomena

1103 Words

Document ID:69119111078

**Memorandum:** There is only void

**Classification** ☐ Omega ☐ Daemon ☒ Stuia ☐ Safe ☒ Recondite ☐ Beneficial  
**Recontainment Measures** ☐ Apokulupto ☐ Extensive ☐ Minimal ☒ Non-applicable




## 1 Specification

S-0121 is a disorder where the brain is replaced with an empty space or void. The disease is characterised by the presence of void mechanisms and brain hyperobjects - a term used to describe certain aspects of the brain that have become distorted or altered due to the disorder. It may represent unusual formations or changes in brain structure that contribute to the disorder's effects.

S-0121's sole known cause is S-0121-1, a doctor's note describing the disorder. S-0121-1 is a weathered, yellowed piece of paper, with the edges slightly frayed from age and use. It has near unintelligible handwriting that describes the effects of S-0121, and prescribes an unknown entity to take S-0121-2.

S-0121-2 is a box of pills that accompanies the doctor's note. The pills are housed in a cylindrical container with a translucent dark orange body and a white cap. The container is made of a smooth and slightly transparent material, allowing a glimpse of the pills inside. The pills are small, diamond-shaped and measure about 10 mm in length and 6 mm in width, emitting a subtle, luminescent blue glow.



**Fig. 1.** An extract of S-0121-1, taken on its first encounter with the Corporation

## 2 Containment Procedures

Since S-0121-1 is the sole known cause of S-0121, it should be placed in a standard containment locker, under high surveillance. An exclusion zone of 1 m is recommended around its location to avoid accidental close proximity to S-0121. S-0121-2 should be kept in a separate secured location, for use in the event that the disorder infects a potential victim, either during transportation or a containment breach. The cap on S-0121-2 should be properly attached.

## 3 Behaviour

When people come into proximity of S-0121-1, they start to feel the effects of S-0121, which causes severe degeneration in brain function, slowly reducing mental capacity until they become horrifically unintelligent. Symptoms may include dysarthria resulting in slurred speech, memory loss and paralysis.

If a pill from S-0121-2 is taken, the disorder's symptoms cease on the victim, but effects of the disorder gets worse for future entities. S-0121-1, the doctor's note, updates to reflect this change. It is unknown how severe the original ailment was, or what was originally written on the doctor's note. On taking a pill from S-0121-2, S-0121-2 creates a new one within itself, leading to a never ending supply of pills.

Below follows the original assessments given to understand S-0121.

**Behavioural Assessment 1** It is hypothesised that prolonged exposure to S-0121-1 leads to the manifestation of initial symptoms of S-0121 in human subjects. 30 Category-C personnel were each introduced to S-0121-1, and were instructed to hold and read the note. Immediate physiological or neurological responses included dizziness, headache, and mild difficulty in cognitive tasks. All 30 test subjects continued showing mild symptoms after being removed from the Experimentation laboratory.

A CT scan of select Category-C's brain showed small, sporadic, empty pockets within the brain structure, measuring a few millimetres in diameter.

### [FURTHER TESTING APPROVED]

**Behavioural Assessment 2** S-0121-1 was deciphered remotely using predictive text models. An autonomous robot was used to interact with it. The note accurately described the symptoms recorded in Behavioural Assessment 1. The note continued on, ordering 1 pill to be taken to cure symptoms in the patient. [See addendum 1] [FURTHER TESTING APPROVED]

**Behavioural Assessment 3** The 30 Category-C personnel from Behavioural Assessment 1 were split into 2 groups. The control group were given placebo pill, while the other group were given one of the pills from within S-0121-2. The number of pills observed within the bottle did not change after administering the pills. All 15 Category-C who took the placebo pills recorded

no changes in described symptoms, and further CT scans showed no further degradation than recorded earlier. Meanwhile the other group's symptoms were cured instantaneously, and CT scans showed signs of brain recovery and growth in the previously voided areas. **[FURTHER TESTING APPROVED]**

**Behavioural Assessment 4** During transportation of S-0121-1 to the Experimentation laboratory, a Blue Clearance Level holder came into contact with S-0121-1, after not following the necessary safety precautions. On arrival at the laboratory, the member of staff exhibited confusion at the task at hand and constant periods of prolonged staring, before eventually fainting. The symptoms shown by this 1 victim were much more severe than those recorded in earlier assessments. A CT scan of the victim's brain showed a slightly larger void within the brain structure, measuring a centimetre in diameter.

However, with such a small sample size, further testing is required. S-0121-1's content was also observed to change, describing different symptoms that aligned with the staff member's predicament. **[FURTHER TESTING APPROVED]**

**Behavioural Assessment 5** The effected staff member was given 1 pill from S-0121-1, as was described in S-0121-2. Upon taking the pill, the member immediately stopped showing signs of S-0121, and was escorted off-site for disciplinary action due to breaking protocol. **[FURTHER TESTING APPROVED]**

**Behavioural Assessment 6** With such conclusive results thus far, a smaller number of test subjects were chosen for this assessment. 3 Category-C personnel were instructed to hold S-0121-1. Within seconds, all 3 test subjects exhibited similar symptoms, with speech slurring, symptoms of dissociation and abnormal euphoria. Again, all 3 symptoms were accurately described on S-0121-1 after the fact, and each subject was given a pill which stopped all symptoms. Further testing is not required for now. **[TESTING CONCLUDED]**

## 4 Origination

The origin of S-0121 and its artefacts is unclear. The doctor's note has been carbon dated to show it is roughly 47 years old. However, as with all anomalous entities, this is inconclusive evidence. S-0121-1 and S-0121-2 were first located together under the floorboards within the US Governments Senate chamber, during a renovation of the Senate Chamber. The extent to which politicians succumbed to the effects of S-0121 are unclear, due to the nature of their work and inconsistent policies overtime. The renovator who found S-0121's artefacts was considered collateral damage, and after testing, any brain degradation was so mild it was considered insignificant enough to warrant further action.

The appearance of the luminescent pills led to the Corporation taking possession of S-0121-1 and S-0121-2 to understand what their properties were. The [REDACTED] operative team were tasked with bringing in all artefacts, but due to the unknown properties of S-0121 at the time,

it is predicted that mild brain degradation has occurred within all team members. Due to the ever worsening symptoms shown by taking the pills within S-0121-2, the unfortunate decision to terminate all team member's contracts was undertaken.

## 5 Postscript

### 5.1 Addendum 1

The following is an extract of the deciphered text found on S-0121-1.

The patient presents with peculiar manifestations indicative of the disorder [S-0121] - namely dizziness, headaches... caused by unsettling void mechanisms that have appeared within the brain, causing distortions in brain hyperobjects. Consume a single pill orally, as needed, to alleviate the torment of this disorder. Keep the pills in the cylindrical container provided, safeguarded from prying eyes. Store the container away from light and heat, as any tampering with the pills may yield unforeseen consequences.